// App-Quantinova.ai

1013 : Prognostic value of natural killer cell activity and derived neutrophils-to-lymphocytes ratio in non-small cell lung cancer patients receiving immune checkpoint inhibitors

Researchers

Presenter

  • Line Nederby

Principal Investigators

  • Sara Wen

  • Christa Nyhus

  • Lisbeth Bertelsen

  • Rikke Andersen

  • Anders Jakobsen

  • Torben Hansen

Medical Centers

  • Vejle Hospital and University of Southern Denmark, Vejle, Denmark

Locations

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

  • Interferon-gamma

  • Interferon

Drug/Treatment

  • Interferon Gamma

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved